Convalescent plasma is ineffective for covid-19 Editorial Article Lessons from the Placid Trial Convalescent plasma generated great enthusiasm in the earliest days of the coronavirus
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) Research Abstract Objective:
Remdesivir has little or no impact on survival for COVID-19, WHO trial shows. The largest trial to date of treatments repurposed for use in the
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 Research Abstract BACKGROUND Hydroxychloroquine and chloroquine have been proposed as treatments for coronavirus disease 2019 (Covid-19) on
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients
Study Name: Association of Race With Mortality Among Patients Hospitalized With Coronavirus Disease 2019 (COVID-19) at 92 US Hospitals Question: Is race associated with mortality
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) to Yale School of Public Health for its SalivaDirect COVID-19 diagnostic test, which